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10 6 /l, range 64–432; p = 0.015).  Conclusion: Climacteric low-
ers the level of PMP but has no impact on the number of EMP 
in women. These data suggest that PMP and EMP do not play 
a significant role in enhancing the risk of thrombotic events 
in healthy, postmenopausal women. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 In premenopausal women with regular menstrual cy-
cles, the hormonal axis is controlled by the hypothalamus 
and the hypophysis. Follicle-stimulating hormone (FSH) 
released in the hypophysis stimulates the maturation of 
ovarian follicles, which in turn produce estradiol. Exert-
ing a positive feedback, the increasing estradiol concen-
trations lead to elevated levels of luteinizing hormone 
during the follicular phase of the menstrual cycle trigger-
ing ovulation. During treatment with oral contraceptives 
(OC), the continuous administration of gestagens or the 
combined administration of gestagens and ethinylestra-
diol results in constant hormonal levels under which FSH 
and luteinizing hormone concentrations remain un-
changed  [1] .
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 Abstract 
 Background: Climacteric increases the risk of thrombotic 
events by alteration of plasmatic coagulation. Up to now, less 
is known about changes in platelet- (PMP) and endothelial 
cell-derived microparticles (EMP).  Methods: In this prospec-
tive study, plasma levels of microparticles (MP) were com-
pared in 21 premenopausal and 19 postmenopausal wom-
en.  Results: No altered numbers of total MP or EMP were 
measured within the study groups. However, the plasma val-
ues of CD61-exposing MP from platelets/megakaryocytes 
were higher in premenopausal women (5,364   ! 10 6 /l, range 
4,384–17,167) as compared to postmenopausal women 
(3,808  ! 10 6 /l, range 2,009–8,850; p = 0.020). This differen-
tiation was also significant for the subgroup of premeno-
pausal women without hormonal contraceptives (5,364  ! 
10 6 /l, range 4,223–15,916; p = 0.047; n = 15). Furthermore, in 
premenopausal women, higher plasma levels of PMP expos-
ing CD62P were also present as compared to postmeno-
pausal women (288  ! 10 6 /l, range 139–462, vs. 121  ! 10 6 /l, 
range 74–284; p = 0.024). This difference was also true for 
CD63+ PMP levels (281  ! 10 6 /l, range 182–551, vs. 137  ! 
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 In Europe, women reach the menopause at around the 
age of 54 years  [2] . At this time, there are less than a thou-
sand follicles remaining in the ovaries leading to de-
creased levels of estradiol  [3] . Through a feedback mech-
anism, the hypophysis increases the production and dis-
tribution of FSH in order to stimulate the ovaries. 
Menopausal symptoms such as hot flushes, sweating, 
vaginal atrophy and osteoporosis are a consequence of 
the decreased estadiol levels. However, climacteric is also 
responsible for a dramatic increase in the risk of adverse 
thrombotic events such as myocardial infarction, stroke, 
deep venous thrombosis and pulmonary embolism  [4] .
 Up to now, most investigations regarding the changes 
in the coagulation system focus on plasmatic factors and 
show inconstant laboratory findings: plasma concentra-
tions of fibrinogen and fibrin D-dimer, both markers of 
thrombotic risk, are elevated, and endogenous fibrino-
lytic activity is reduced in healthy postmenopausal wom-
en as compared to younger women  [5] ; however, inhibi-
tors like protein C, protein S, antithrombin, or tissue fac-
tor pathway inhibitor are also increased in menopausal 
women  [6] . In view of these findings, climacteric seems 
to destabilize the plasmatic coagulation system.
 Less is known about changes of platelets and endothe-
lial cells which could also play a role in the observed en-
hancement of thrombotic risk during aging. One way to 
determine the activation status of platelets as well as of 
endothelial cells in vivo is to measure microparticle (MP) 
concentrations in plasma. MP can be released from every 
blood and endothelial cell into the peripheral circulation. 
However, in healthy humans, MP are mainly CD61+ and 
are derived from megakaryocytes or from platelets (plate-
let-derived microparticles, PMP) with additional expos-
ing of the platelet activation markers P-selectin and CD63 
 [7] . In particular, the composition and function of PMP 
have been intensively analyzed  [8, 9] . PMP are major play-
ers in coagulation  [10] as they are highly thrombogenic 
 [11] because of their phospholipid surfaces with binding 
sites for several different coagulation factors  [12, 13] . 
PMP are important initiators of coagulation and provide 
a link between the platelet-based hemostatic system and 
plasmatic coagulation in vivo. Patients with Glanzman’s 
disease  [14] or Scott Syndrome  [15] have reduced counts 
of PMP leading to bleeding disorders. On the other hand, 
patients with elevated levels of PMP suffer from diseases 
like cerebral infarction  [16] , acute coronary syndrome 
 [17] , sepsis  [18] and venous thrombosis  [19] . In the latter 
cases, MP from endothelial cells (EMP) are also regular-
ly increased, reflecting injuries to the endothelial surface 
of the vessels. However, it is not known whether these in-
creased levels of PMP and EMP are the consequence or 
the cause of hypercoagulation.
 Within this prospective case-control study, the impact 
of climacteric on plasma levels of PMP and EMP in 
healthy women was investigated. As surrogate markers 
for the activation status of platelets, megakaryocytes and 
endothelial cells, they may play a possible role in trigger-
ing thrombotic events in postmenopausal women.
 Patients and Methods 
 Study Population and Trial Design 
 In this prospective case-control study, 21 premenopausal 
women with or without hormone-containing OC were compared 
with a group of 19 menopausal women. Patients were screened 
and recruited from the Department of Obstetrics and Gynecolo-
gy, Ludwig-Maximilians University, Klinikum Grosshadern, 
Munich, Germany, between November 2007 and July 2009. Wom-
en taking other medications except OC were excluded, especially 
postmenopausal women taking hormone replacement therapy. 
Participants were asked about their menstrual pattern or, accord-
ingly, their last cycle. Premenopausal women were only enrolled 
in the study if they have got a normal frequent menstrual cycle 
between 21 and 35 days within the last year at least. The time point 
of blood sampling in this group was estimated during women’s 
follicular phase between menses and ovulation. Postmenopausal 
women were only included in the study if their last menstrual 
cycle dated back 1 year or longer. Furthermore, the history of ve-
nous thromboembolism (VTE) or other disorders was evaluated 
and women with a history of VTE were excluded. All included 
participants were Caucasians and had to have normal blood 
counts as well as normal prothrombin time and activated partial 
thromboplastin time, normal fibrinogen plasma levels, and nega-
tive D-dimer at the time of investigation. To avoid other possible 
confounders in our study, there were further criteria which the 
women had to fulfill before they were enrolled: a normal body 
mass index between 19 and 25 (calculated after measuring height 
and weight), normal blood pressure  ! 140/90 mm Hg (checked at 
the time point of blood sampling), non-smoking, no history of 
disorders and no long-time medication as well as no acute medi-
cation within the last week before blood sampling.  The Human 
Investigation Review Board of the Ludwig-Maximilian Univer-
sity Munich approved the study. Signed informed consent was 
obtained from all women allowing analysis of all clinical and lab-
oratory data mentioned in this paper.
 Blood Sampling and Isolation of MP 
 Blood samples were taken by puncture of the antecubital vein 
without tourniquet through a 20-gauge needle. For isolation of 
MP, blood samples were centrifuged at 1,550  g for 20 min within 
15 min after sampling and stabilized in liquid nitrogen for 15 min. 
Samples were stored at –80   °   C until assayed. Samples were de-
frosted carefully over a period of approximately 1 h. After cen-
trifugation of 250   l plasma at 18,890  g for 30 min, 225   l of 
plasma/supernatant was removed. MP were resuspended after the 
addition of 225   l phosphate-buffered saline (PBS) containing 
citrate (0.32% trisodiumcitrate) and centrifuged again for 30 min 
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at 18,890  g. After removal of the supernatant (225 ml), 75   l of 
PBS/citrate buffer was added, and the MP pellet was resuspended. 
Five microliters of the MP suspension was diluted in PBS contain-
ing 35   l CaCl 2 (2.5 mmol/l) or, alternatively, 35   l citrate for 
annexin-V-negative controls. Finally, 5   l annexin V was added 
plus 5   l of each cell-specific monoclonal antibody or isotype-
matched control antibodies and incubated in the dark at room 
temperature for 15 min. The reaction was stopped with 900   l of 
PBS containing calcium (2.5 mmol/l).
 Reagents 
 EMP were identified via double staining with APC-labeled an-
nexin V (Immuno Quality Products, Groningen, The Nether-
lands) and a fluorescein isothiocyanate (FITC)-labeled anti-
CD144 antibody (Acris, Hiddenhausen, Germany). PMP were de-
tected via allophycocyanin (APC)-labeled annexin V, FITC-labeled 
anti-CD61 antibody (Immuno Quality Products), and anti-
CD62P antibody (Immunotech, Marseille, France) or anti-CD63 
antibody (Immunotech) as a platelet activation marker. IgG-FITC 
and IgG-phycoerythrin (IgG-PE), both from BD Biosciences 
(Heidelberg, Germany), were used as antibody negative controls. 
All antibodies and annexin V were diluted with PBS (154 mmol/l 
NaCl, 1.4 mmol/l phosphate, pH 7.4). Final dilutions were: annex-
in-V-APC 1: 300 (v/v), anti-CD144-FITC 1: 20, anti-CD61-FITC 
1: 100, anti-CD62P-PE 1: 100, anti-CD63-PE 1: 20, anti-IgG-FITC 
1: 100, and anti-IgG-PE 1: 100.
 Analysis of Microparticle 
 The samples were analyzed in a FACScan flow cytometer (BD 
Biosciences, Heidelberg) running Cell Quest Software (BD Bio-
sciences, San Jose, Calif., USA) which was calibrated daily using 
beads from BD Biosciences (Heidelberg). FACScan was run on 
high pressure. Forward scatter, sideward scatter and fluorescence 
channels were set at logarithmic gain. All samples were analyzed 
for 1 min. The volume analyzed in 1 min (V; approximately 50–80 
  l) was measured daily before analysis by taking the weight of a 
sample (aqua dest) before and after analysis. The gating strategy 
is described in  figure 1 . The number of MP/  l of plasma was de-
termined by using the following formula: MP/l = n  ! (100   l/
5   l)  ! (950   l/V)  ! (106/250   l) according to Berckmans et al. 
 [20] , where n = absolute number of MP determined by FACS anal-
ysis; 100   l = total volume of washed microparticle suspension; 
5   l = pellet used for analysis; 950   l = total volume before analy-
sis (pellet + antibodies + buffer); 250   l = original volume of the 
sample before isolation of MP.
 Statistical Methods 
 Results are given as median values with interquartile ranges, 
if not otherwise indicated. Differences between the groups were 
analyzed by the non-parametric Mann-Whitney test. All statisti-
cal tests were two-tailed. p values  ! 0.05 were regarded as statisti-
cally significant. Data were analyzed with SPSS for Windows, re-
lease 18.0.
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 Fig. 1. Identification of MP by flow cytom-
etry. AU = Arbitrary units.  a MP can be 
found in region 1 (R1) by their dimension, 
as described by Nieuwland et al.  [12] . 
SSC = Sideward scatter; FSC = forward 
scatter.  b For negative control, MP were 
double stained with unspecific antibody 
IgG plus annexin V in a Ca 2+ -free buffer 
(R2).  c Annexin V in Ca 2+ -containing buf-
fer identifies phosphatidylserine on the 
MP surface with high specificity and sen-
sitivity (R3).  d Double staining of annexin 
V plus antigen (AG)-specific antibody 
(here: anti-CD61) determines the cell ori-
gin of MP (R4). 
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 Results 
 Study Population 
 The median age of the 21 premenopausal women was 
27 years (Q25: 23 years, Q75: 35 years, range 18–40). All 
had regular menstrual cycles. Fifteen women had not 
been taking OC or other hormone-containing contracep-
tives for at least 1 year prior to the time of analysis. Six 
premenopausal women were taking OC containing 0.03 
mg ethinylestradiol and 2 mg dienogest (Valette  ). Nine-
teen women were postmenopausal for at least 1 year with 
a median age of 61 years (Q25: 56 years, Q75: 66 years, 
range 53–70). None of the pre- and postmenopausal 
women had a history of VTE or any other diseases.
 Microparticle Analysis 
 Counts of total annexin-V-positive MP did not differ 
between pre- and postmenopausal women. Similarly, no 
differences were measured in the numbers of CD144-ex-
posing endothelial cell-derived MP ( table 1 ). In contrast, 
the value of platelet-derived CD61-exposing MP was sig-
nificantly higher in the premenopausal group (p = 0.02) 
compared to postmenopausal women ( fig. 2 ). This differ-
ence was also significant for the subgroup of premeno-
pausal women without contraception (p = 0.047). The 
highest values were measured in premenopausal women 
taking OC but without statistical significance because of 
the small number of women investigated. The plasma lev-
els of PMP exposing the activation markers P-selectin 
and CD63 were also increased in women before the meno-
pause (p = 0.024 and 0.015, respectively). However, the 
percentage fraction of PMP-exposing activation markers 
was similar in all investigated (sub-)groups: a median val-
ue of 4.1% was observed in premenopausal women (4.1% 
without OC, 3.7% with OC) versus 4.1% in postmeno-
pausal women (CD62P+ PMP), along with 4.3% CD63+ 
PMP in premenopausal women (4.3% without OC and 
4.3% with OC vs. 4.9% in postmenopausal women).
 Discussion 
 Our data demonstrate lower plasma levels of CD61-
exposing MP in postmenopausal women. These results 
may seem surprising as PMP are prothrombogenic and 
potent stimulators of coagulation. Therefore, higher 
CD61+ MP in postmenopausal women would be expect-
ed, possibly explaining the increased risk of thrombotic 
events in this population. Indeed, patients suffering from 
acute deep venous thrombosis or pulmonary embolism 
showed elevated counts of PMP  [21, 22] . Ramacciotti et 
al.  [23] could even show a positive correlation between 
thrombus weight and level of PMP in a mouse model. 
However, the elevated PMP levels reported in these other 
studies were present in patients with manifest thrombot-
ic events.
 Up to now, platelets were thought to be the major cell 
source of CD61+ MP. Accordingly, circulating CD61+ 
MP are commonly called ‘platelet-derived microparti-
cles’ in the literature. Nevertheless, more than 10 years 
ago, Cramer et al.  [24] showed via electronic microscopy 
in cell cultures that megakaryocytes constrict not only 
platelets but also CD61+ MP simultaneously. As mega-
karyocytes eject platelets directly into the blood through 
cytoplasmic processes penetrating the sinus wall into the 
sinus lumen  [25] , this may also result in the concurrent 
release of megakaryocyte-derived MP into the circula-
tion. Although the regulation of megakaryopoiesis is not 
yet exactly understood, the female steroid hormone es-
trogen has been identified as an endogenous activator of 
differentiation, proliferation and proplatelet formation as 
well as of the constriction of megakaryocytic MP. The 
estrogen receptor is expressed on megakaryocytes  [26] . 
Estradiol and progesterone are synthesized in male as 
well as female megakaryocytes indicating an autocrine 
stimulation loop of megakaryopoiesis  [27] . Furthermore, 
addition of extracellular estradiol enhances proplatelet 
formation in a dose-dependent manner and an estrogen 
Table 1. M P in pre- and postmenopausal women
Total MP CD61+ MP CD62P+ PMP CD63+ PMP EMP
Premenopausal women (n = 21) 6,159 (4,427–15,023) 5,364 (4,384–17,167)* 288 (139–462)* 281 (182–551)* 347 (207–499)
Without OC (n = 15) 6,159 (4,325–13,577) 5,364 (4,223–15,916)* 209 (108–455) 276 (140–535)* 376 (265–539)
With OC (n = 6) 7,168 (4,045–16,730) 7,303 (4,096–18,465) 323 (178–536) 314 (250–658)* 289 (173–502)
Postmenopausal women (n = 19) 6,484 (3,639–8,419) 3,808 (2,009–8,850) 121 (74–284) 137 (64–432) 495 (198–711)
D ata are median MP ! 106/l, with interquartile ranges in parentheses. * p < 0.05 compared to postmenopausal women.
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receptor antagonist inhibits platelet production in vivo. 
This would explain the higher levels of CD61-exposing 
MP in premenopausal women compared to those detect-
ed in postmenopausal women who are known to have no 
relevant estrogen level any more. In line with this conclu-
sion, we found the highest counts of CD61-exposing MP 
in premenopausal women who took estrogen-containing 
contraceptives, even though the number of investigated 
women is small and limits the validity of our data. But the 
idea of a relevant influence of female hormones on the 
plasma level of CD61+ MP is supported by recent pub-
lished data from our group: this subtype of plasma MP is 
higher in postmenopausal women with hormone replace-
ment therapy compared to those without hormone re-
placement therapy  [28] . The general relevance of estro-
gens becomes evident by the fact that women have higher 
mean counts of platelets as well as of CD61-exposing 
MP – probably mainly derived from megakaryocytes – 
than men  [29] .
 Unfortunately, it is not possible to distinguish MP re-
leased from platelets and megakaryocytes using common 
detecting antigens like fibrinogen (CD41/CD61), or von 
Willebrand receptor (CD42a and CD42b), as they are ex-
pressed on the surface of both cell types. Recently, how-
ever, by measuring full-length filament A and, accord-
ingly, lysosome-associated membrane glycoprotein 1 in 
CD41/CD42b-exposing MP, it was shown that indeed 
‘PMP’ without activation markers originate largely from 
megakaryocytes in mice  [30] . Data from our own inves-
tigations indicate that this is also true in humans: killing 
megakaryocytes by total body irradiation in patients un-
dergoing stem cell transplantation leads to a faster de-
cline in CD61-exposing MP than in platelets  [31] . Thus, 
the main population of CD61+ MP seems to be directly 
derived from megakaryocytes and only a small fraction, 
around 3–5% in healthy humans  [32] , are released from 
platelets after cell activation. This fraction of ‘real PMP’ 
is released from activated platelets because of various rea-
sons like high shear stress around a vessel stenosis  [33, 34] 
in patients with myocardial infarction, intermittent clau-
dicatio, or ischemic events  [35, 36] . In our study popula-
tion without a history of such disorders, the percentage 
of platelet activation marker-positive MP in pre- and 
postmenopausal women was comparable with data from 
the literature.
 We also investigated EMP levels in pre- and post-
menopausal healthy women. As a specific and general 
marker for MP derived from vascular endothelium we 
used  vascular endothelium-cadherin (CD144) which is 
thought to play an important role in endothelial cell biol-
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ogy by controlling the cohesion and organization of the 
intercellular junctions  [37] . Endothelium injury raises the 
level of circulating, CD144-exposing EMP as shown in 
patients with atherosclerosis and especially in those with 
plaque instability  [38, 39] . We did not find different levels 
of CD144 positivity in any investigated (sub-)group. This 
indicates vessel wall integrity without any damage or ac-
tivation of endothelial cells within our study population.
 Summing up, postmenopausal women who are known 
to be at high risk for vascular events showed lower PMP, 
probably because of female hormone deficiency. Further-
more, climacteric does not seem to have an influence on 
the number of EMP in healthy women. From a clinical 
point of view, our data show that neither PMP nor EMP 
are responsible for enhancing the risk of venous or arte-
rial thromboembolism in menopausal women. Our find-
ings are the first published impression of the impact of 
the climacteric on MP serum levels, but a higher number 
of participants is necessary to confirm our results. Fur-
thermore, in a next step, we will also go more into detail 
of qualitative MP changes, e.g., the frequency of tissue 
factor-bearing MP.
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